Abstract | OBJECTIVE: To determine whether a multibiomarker disease activity ( MBDA) score predicts radiographic damage progression in the subsequent year in patients with early rheumatoid arthritis. METHODS: There were 180 serum samples available in the BeSt study (trial numbers NTR262, NTR 265): 91 at baseline (84 with radiographs available) and 89 at 1-year followup (81 with radiographs available). Radiographs were assessed using the Sharp/van der Heijde Score (SvdH). Twelve serum biomarkers were measured to determine MBDA scores using a validated algorithm. Receiver-operating curves and Poisson regression analyses were performed, with Disease Activity Score ( DAS) and MBDA score as independent variables, and radiographic progression as dependent variable. RESULTS: At baseline, MBDA scores discriminated more between patients who developed radiographic progression (increase in SvdH≥5 points) and patients who did not [area under the curve (AUC) 0.767, 95% CI 0.639-0.896] than did DAS (AUC 0.521, 95% CI 0.358-0.684). At 1 year, MBDA score had an AUC of 0.691 (95% CI 0.453-0.929) and DAS had an AUC of 0.649 (95% CI 0.417-0.880). Adjusted for anticitrullinated protein antibody status and DAS, higher MBDA scores were associated with an increased risk for SvdH progression [relative risk (RR) 1.039, 95% CI 1.018-1.059 for baseline MBDA score; 1.037, 95% CI 1.009-1.065 for Year 1 MBDA score]. Categorized high MBDA scores were also correlated with SvdH progression (RR for high MBDA score at baseline 3.7; low or moderate MBDA score as reference). At 1 year, high MBDA score gave a RR of 4.6 compared to low MBDA score. CONCLUSION:
MBDA scores predict radiographic damage progression at baseline and during disease course.
|
Authors | Iris M Markusse, Linda Dirven, Marianne van den Broek, Casper Bijkerk, K Huub Han, H Karel Ronday, Rebecca Bolce, Eric H Sasso, Pit J S M Kerstens, Willem F Lems, Tom W J Huizinga, Cornelia F Allaart |
Journal | The Journal of rheumatology
(J Rheumatol)
Vol. 41
Issue 11
Pg. 2114-9
(Nov 2014)
ISSN: 0315-162X [Print] Canada |
PMID | 25128518
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antirheumatic Agents
- Biomarkers
|
Topics |
- Aged
- Antirheumatic Agents
(therapeutic use)
- Area Under Curve
- Arthritis, Rheumatoid
(blood, diagnostic imaging, drug therapy)
- Arthrography
(methods)
- Biomarkers
(blood)
- Confidence Intervals
- Disease Progression
- Female
- Humans
- Joints
(pathology)
- Male
- Middle Aged
- Monitoring, Physiologic
- Netherlands
- Poisson Distribution
- Predictive Value of Tests
- Prognosis
- Risk Assessment
- Sensitivity and Specificity
- Severity of Illness Index
- Time Factors
|